AJOVista LLC Makes New Investment in Evolus, Inc. (NASDAQ:EOLS)

AJOVista LLC acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 6,682 shares of the company’s stock, valued at approximately $70,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Evolus by 353.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company’s stock valued at $70,000 after acquiring an additional 5,155 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Evolus by 13.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock valued at $113,000 after acquiring an additional 1,484 shares in the last quarter. Teza Capital Management LLC purchased a new position in shares of Evolus during the 3rd quarter valued at $136,000. Kestra Advisory Services LLC grew its holdings in shares of Evolus by 18.5% during the 3rd quarter. Kestra Advisory Services LLC now owns 16,356 shares of the company’s stock valued at $149,000 after acquiring an additional 2,550 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Evolus in the third quarter worth $171,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EOLS has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, April 10th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Friday, March 1st. Finally, Barclays raised shares of Evolus from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $10.00 to $16.00 in a research report on Monday, January 29th.

Insider Activity

In related news, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $78,954.24. Following the transaction, the chief financial officer now directly owns 154,201 shares in the company, valued at $2,146,477.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Evolus news, insider David Moatazedi sold 7,706 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $13.08, for a total value of $100,794.48. Following the sale, the insider now directly owns 792,416 shares in the company, valued at $10,364,801.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the sale, the chief financial officer now owns 154,201 shares in the company, valued at $2,146,477.92. The disclosure for this sale can be found here. Insiders have sold 49,038 shares of company stock valued at $674,232 over the last three months. 5.40% of the stock is owned by insiders.

Evolus Stock Performance

Shares of EOLS traded up $0.08 during trading hours on Friday, reaching $13.30. 1,126,051 shares of the company traded hands, compared to its average volume of 505,959. The stock’s fifty day moving average is $13.31 and its 200 day moving average is $11.42. The stock has a market cap of $832.45 million, a P/E ratio of -12.20 and a beta of 1.47. Evolus, Inc. has a 1-year low of $7.07 and a 1-year high of $15.43.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $61.00 million for the quarter, compared to analysts’ expectations of $61.14 million. On average, equities research analysts predict that Evolus, Inc. will post -0.51 EPS for the current year.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.